CytoCore, Inc. (CCI) develops, and plans to sell, integrated family products for the detection, diagnosis and treatment of cancer under the trade name of CytoCore Solutions. CytoCore Solutions products are intended to address sample collection, specimen preparation, specimen evaluation (including detection/screening and diagnosis), treatment and patient monitoring within vertical markets related to specific cancers. CytoCore Solutions products are focused upon cervical and breast cancer. The Company's marketed product is the SoftPAP cell collection device that is intended to replace the spatula and brush used to collect cervical cytology samples. The Halo System, which the Company is selling for the assessment of breasts cancer. The other components of the CytoCore Solutions System include certain biochemical assays and slide-based tests, plus the Company's next generation specialized system for computer-assisted cytology-the Automated Image Proteomic Systems ( AIPS).